חוב כולל של החברה: monopartx.com (MNPR)

This chart of the current market value of Monopar Therapeutics (MNPR) reflects the price action of a company developing anti-tumor agents. Net debt stands at 0.00. The business relies on the increasing value of its patents, as positive test results provide access to highly profitable global markets. A lean executive team ensures a rapid strategic pivot toward new radiopharmaceutical alliances, although shareholder confidence remains heavily dependent on medical reports.

This indicator measures the total volume of external liabilities, reflecting the issuer's dependence on debt financing. The calculation is based on real-time monitoring of credit lines and bond loans. By analyzing the amount of debt capital on GURU.Markets, an investor assesses the business's financial stability. For Monopar Therapeutics (MNPR), the absence of debt confirms the autonomy of its oncology drug development. This is critical, as the company's future market value relies exclusively on the patent protection of new molecules.